Stanford V


Stanford V is a chemotherapy regimen intended as a first-line treatment for Hodgkin lymphoma. The regimen was developed in 1988, with the objective of maintaining a high remission rate while reducing the incidence of acute and long term toxicity, pulmonary damage, and sterility observed in alternative treatment regimens such as ABVD. The chemical agents used are:
Drug Regimen
DrugDoseModeDays
Doxorubicin25 mg/m2IVDays 1 and 15
Vinblastine6 mg/m2IVDays 1 and 15
Chlormethine6 mg/m2IVDay 1
Vincristine1.4 mg/m2 IVDays 8 and 22
Bleomycin5 units/m2IVDays 8 and 22
Etoposide60 mg/m2IVDays 15, 16
Prednisone40 mg/m2POQ2D

The chemotherapy part of Stanford V treatment can last anywhere from 8 to 12 weeks, depending on the staging of the disease. In many cases, this is followed by radiation therapy for anywhere from 2 to 6 weeks to the affected areas of the body.
Stanford V is a more rigorously administered form of chemotherapy, with treatments roughly twice as fast as those of other Hodgkin lymphoma treatments. However, in a randomized controlled study, Stanford V was inferior to ABVD. This study has been criticized for not adhering to the proper Stanford V protocol. Specifically, the radiation therapy component following chemotherapy was not properly administered in the Italian study. A retrospective study from the Memorial Sloan-Kettering Cancer Center displayed results similar to the Stanford Cancer Center's own experience. The study concluded that, "Stanford V with appropriate radiotherapy is a highly effective regimen for locally extensive and advanced HL."